Food Allergy News and Research

Different Skin Structure in Some People With Eczema Could Play a Role in Food Allergy Development

Researchers at National Jewish Health and their colleagues have identified structural and molecular markers in the skin of atopic dermatitis patients that distinguish those who have food allergies from those who do not. The findings strengthen emerging science indicating that the skin plays a major role in food allergies, and suggest that personalized treatments for a subset of atopic dermatitis patients might help prevent food allergies.

DBV to Resubmit Viaskin Peanut Treatment for FDA Biologics License

Kids With Food Allergies is sharing this press release from DBV Technologies to bring you the latest research news quickly. [PRESS RELEASE] DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of PeanutAllergic Children 4 to 11 Years of Age Progress made to date to enable BLA resubmission in Q3 2019 Company to hold conference call today, February 13th, at 4:30 ET / 22:30 CET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...

FDA Application for Peanut Patch for Children 4 to 11 Years of Age Is Withdrawn

DBV Technologies today announced that after discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut in children four to 11 years of age has been voluntarily withdrawn. DBV is currently working closely with the agency to resubmit the application for Viaskin Peanut as quickly as possible.

New Generic Epinephrine Auto-Injector Now Available in Limited Areas of the U.S.

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced the release of limited doses of the FDA-approved generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg, in the US. Teva’s generic version of the EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg, and an additional supply of Teva’s generic version of the EpiPen® (epinephrine injection, USP) Auto-Injector, 0.3 mg is expected in 2019. The publically-available Wholesale Acquisition Cost (WAC)2

Research Results for New Peanut Allergy Treatment Is Ready for FDA Review

The final research results for a new treatment for protection against accidental exposure to peanut was presented today at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting and published in the New England Journal of Medicine. The results show it is possible for some people with peanut allergy to protect themselves from accidental ingestion by building up their tolerance to peanut over time.

Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
1235 South Clark Street Suite 305, Arlington, VA 22202
Phone: 1-800-7-ASTHMA (1.800.727.8462)